



## Clinical trial results:

**A multicentre randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability, efficacy, dose-response, pharmacokinetics and pharmacodynamics of repeat dosing of an anti-LAG3 cell depleting monoclonal antibody (GSK2831781) in patients with active ulcerative colitis**

### Summary

EudraCT number	2018-003278-28
Trial protocol	GB HU CZ FR BG PL NL BE
Global end of trial date	17 May 2021

### Results information

Result version number	v2 (current)
This version publication date	18 April 2022
First version publication date	01 March 2022
Version creation reason	

### Trial information

#### Trial identification

Sponsor protocol code	204869
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Public contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 August 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 May 2021
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

- To evaluate the safety and tolerability of repeat doses of GSK2831781 during the Double-Blind Induction Phase.
- To characterise the efficacy dose response of GSK2831781 during the Double-Blind Induction Phase

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 May 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Czechia: 4
Country: Number of subjects enrolled	France: 5
Country: Number of subjects enrolled	India: 3
Country: Number of subjects enrolled	Japan: 1
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Poland: 46
Country: Number of subjects enrolled	Russian Federation: 8
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	South Africa: 5
Country: Number of subjects enrolled	Ukraine: 17
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	United States: 7
Worldwide total number of subjects	104
EEA total number of subjects	59

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	100
From 65 to 84 years	4
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This was a randomized, placebo-controlled study to evaluate the safety, tolerability, efficacy and dose-response of GSK2831781 in participants with ulcerative colitis. The study was conducted across 13 countries.

### Pre-assignment

Screening details:

A total of 104 participants were enrolled in the study. This study was terminated based on the assessment of clinical data.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo IV

Arm description:

Participants were administered placebo via the intravenous (IV) route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants from the placebo arm identified as responders based on Week 10 assessments during the Induction Phase received placebo subcutaneously (SC) every 4 weeks from Weeks 14 to 26 during the 20 week double-blind extended treatment phase (ETP). At Week 30, participants underwent an assessment following which they were followed up until Week 42.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion, Concentrate and solvent for concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was 0.9% weight/volume (w/v) sodium chloride solution to be administered via the IV route

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo was 0.9% w/v sodium chloride solution to be administered via the SC route

<b>Arm title</b>	GSK2831781 450 mg IV
------------------	----------------------

Arm description:

Participants were administered GSK2831781 450 milligrams (mg) via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-

week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Arm type	Experimental
Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 mg/mL to be administered via the SC route

Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 milligrams per milliliter (mg/mL) to be administered via the IV route

<b>Arm title</b>	GSK2831781 300 mg IV
------------------	----------------------

Arm description:

Participants were administered GSK2831781 300 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Arm type	Experimental
Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 mg/mL to be administered via the SC route

Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 milligrams per milliliter (mg/mL) to be administered via the IV route

<b>Arm title</b>	GSK2831781 150 mg IV
------------------	----------------------

Arm description:

Participants were administered GSK2831781 150 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from

the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Arm type	Experimental
Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 mg/mL to be administered via the SC route

Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 milligrams per milliliter (mg/mL) to be administered via the IV route

<b>Arm title</b>	GSK2831781 45 mg IV
------------------	---------------------

Arm description:

Participants were administered GSK2831781 45 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Arm type	Experimental
Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 mg/mL to be administered via the SC route

Investigational medicinal product name	GSK2831781
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

GSK2831781 was available as solution at unit dose strength of 150 milligrams per milliliter (mg/mL) to be administered via the IV route

<b>Number of subjects in period 1</b>	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV
Started	27	48	11
Completed	3	9	0
Not completed	24	39	11
Consent withdrawn by subject	4	6	-
Physician decision	-	1	-
Protocol-specified withdrawal criterion met	-	2	-
Adverse event, non-fatal	-	3	1
Study terminated by sponsor	17	18	10
Lost to follow-up	-	1	-
Lack of efficacy	3	8	-

<b>Number of subjects in period 1</b>	GSK2831781 150 mg IV	GSK2831781 45 mg IV
Started	10	8
Completed	0	0
Not completed	10	8
Consent withdrawn by subject	1	-
Physician decision	-	-
Protocol-specified withdrawal criterion met	-	-
Adverse event, non-fatal	1	-
Study terminated by sponsor	7	8
Lost to follow-up	-	-
Lack of efficacy	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo IV
-----------------------	------------

#### Reporting group description:

Participants were administered placebo via the intravenous (IV) route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants from the placebo arm identified as responders based on Week 10 assessments during the Induction Phase received placebo subcutaneously (SC) every 4 weeks from Weeks 14 to 26 during the 20 week double-blind extended treatment phase (ETP). At Week 30, participants underwent an assessment following which they were followed up until Week 42.

Reporting group title	GSK2831781 450 mg IV
-----------------------	----------------------

#### Reporting group description:

Participants were administered GSK2831781 450 milligrams (mg) via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Reporting group title	GSK2831781 300 mg IV
-----------------------	----------------------

#### Reporting group description:

Participants were administered GSK2831781 300 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Reporting group title	GSK2831781 150 mg IV
-----------------------	----------------------

#### Reporting group description:

Participants were administered GSK2831781 150 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

Reporting group title	GSK2831781 45 mg IV
-----------------------	---------------------

#### Reporting group description:

Participants were administered GSK2831781 45 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.



Reporting group values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV
Number of subjects	27	48	11
Age categorical Units: Participants			
In utero	0	0	0
Preterm newborn infants (gestational age <37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	25	47	11
From 65-84 years	2	1	0
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	43.9	40.7	37.6
standard deviation	± 12.82	± 12.70	± 13.06
Sex: Female, Male Units: Participants			
Female	12	22	4
Male	15	26	7
Race/Ethnicity, Customized Units: Subjects			
Asian-Central/South Asian Heritage	0	1	1
Asian-East Asian Heritage	2	0	0
Asian-Japanese Heritage	0	0	1
Asian-South East Asian Heritage	0	1	0
White-Arabic/North African Heritage	0	1	0
White-White/Caucasian/European Heritage	25	44	9
Mixed White race	0	1	0

Reporting group values	GSK2831781 150 mg IV	GSK2831781 45 mg IV	Total
Number of subjects	10	8	104
Age categorical Units: Participants			
In utero	0	0	0
Preterm newborn infants (gestational age <37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	8	100
From 65-84 years	1	0	4
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	42.5	40.6	

standard deviation	± 15.06	± 10.60	-
--------------------	---------	---------	---

Sex: Female, Male			
Units: Participants			
Female	4	1	43
Male	6	7	61
Race/Ethnicity, Customized			
Units: Subjects			
Asian-Central/South Asian Heritage	0	1	3
Asian-East Asian Heritage	0	0	2
Asian-Japanese Heritage	0	0	1
Asian-South East Asian Heritage	0	0	1
White-Arabic/North African Heritage	0	0	1
White-White/Caucasian/European Heritage	10	7	95
Mixed White race	0	0	1

## End points

### End points reporting groups

Reporting group title	Placebo IV
Reporting group description:	
Participants were administered placebo via the intravenous (IV) route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants from the placebo arm identified as responders based on Week 10 assessments during the Induction Phase received placebo subcutaneously (SC) every 4 weeks from Weeks 14 to 26 during the 20 week double-blind extended treatment phase (ETP). At Week 30, participants underwent an assessment following which they were followed up until Week 42.	
Reporting group title	GSK2831781 450 mg IV
Reporting group description:	
Participants were administered GSK2831781 450 milligrams (mg) via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.	
Reporting group title	GSK2831781 300 mg IV
Reporting group description:	
Participants were administered GSK2831781 300 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.	
Reporting group title	GSK2831781 150 mg IV
Reporting group description:	
Participants were administered GSK2831781 150 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.	
Reporting group title	GSK2831781 45 mg IV
Reporting group description:	
Participants were administered GSK2831781 45 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy. Participants identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42. Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase. Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.	
Subject analysis set title	Placebo SC
Subject analysis set type	Safety analysis

**Subject analysis set description:**

Participants from the placebo arm identified as responders based on Week 10 assessments during the Induction Phase received placebo subcutaneously (SC) every 4 weeks from Weeks 14 to 26 during the 20 week double-blind extended treatment phase (ETP). At Week 30, participants underwent an assessment following which they were followed up until Week 42.

Subject analysis set title	GSK2831781 300 mg SC
Subject analysis set type	Safety analysis

**Subject analysis set description:**

Participants from the GSK2831781 arms identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42.

---

**Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Double-Blind Induction Phase**


---

End point title	Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Double-Blind Induction Phase <sup>[1]</sup>
-----------------	--

**End point description:**

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect or other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were collected up to Week 14 (for participants who later entered the Double Blind ETP) and Week 12 (for participants who later entered OL Induction Phase). Safety Population comprised of all participants who received at least one dose of study treatment.

End point type	Primary
----------------	---------

**End point timeframe:**

Up to a maximum of Week 14

**Notes:**

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

<b>End point values</b>	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[2]</sup>	48 <sup>[3]</sup>	11 <sup>[4]</sup>	10 <sup>[5]</sup>
Units: Participants				
AEs	10	27	6	2
SAEs	0	6	1	0

**Notes:**

[2] - Safety Population

[3] - Safety Population

[4] - Safety Population

[5] - Safety Population

<b>End point values</b>	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[6]</sup>			
Units: Participants				
AEs	2			
SAEs	0			

Notes:

[6] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with worst-case vital signs results by potential clinical importance (PCI) criteria post-Baseline relative to Baseline-Double-Blind Induction Phase

End point title	Number of participants with worst-case vital signs results by potential clinical importance (PCI) criteria post-Baseline relative to Baseline-Double-Blind Induction Phase <sup>[7]</sup>
-----------------	---

End point description:

Vital signs were measured in a seated or semi-supine position after 5 minutes rest. Clinical concern range were: systolic blood pressure (SBP) (lower: <85 and upper: > 160 millimeters of mercury [mmHg]); diastolic blood pressure (DBP) (lower: <45 mmHg and upper: >100 mmHg); pulse rate (PR) (lower: <40 and upper: >110 beats per minute [bpm]) and temperature (Temp) (lower: <35 and upper: >38 degree Celsius). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To within (w/in) Range or No Change category. Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 10

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[8]</sup>	48 <sup>[9]</sup>	11 <sup>[10]</sup>	10 <sup>[11]</sup>
Units: Participants				
DBP; To low; n=27, 47, 9, 8, 7	0	0	0	0
DBP; To w/in range or no change; n=27, 47, 9, 8, 7	27	47	9	8
DBP; To high; n=27, 47, 9, 8, 7	0	0	0	0
SBP; To low; n=27, 47, 10, 9, 6	0	0	1	0
SBP; To w/in range or no change; n=27, 47, 10, 9, 6	26	45	9	9
SBP; To high; n=27, 47, 10, 9, 6	1	2	0	0
PR; To low; n=27, 47, 11, 9, 8	0	1	0	0
PR; To w/in range or no change; n=27, 47, 11, 9, 8	27	45	10	9
PR; To high; n=27, 47, 11, 9, 8	0	1	1	0
Temp; To low; n=26, 46, 11, 10, 7	0	0	0	0
Temp; To w/in range or no change; n=26, 46, 11, 10, 7	26	46	11	10
Temp; To high; n=26, 46, 11, 10, 7	0	0	0	0

Notes:

[8] - Safety Population

[9] - Safety Population

[10] - Safety Population

[11] - Safety Population

<b>End point values</b>	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[12]</sup>			
Units: Participants				
DBP; To low; n=27, 47, 9, 8, 7	0			
DBP; To w/in range or no change; n=27, 47, 9, 8, 7	7			
DBP; To high; n=27, 47, 9, 8, 7	0			
SBP; To low; n=27, 47, 10, 9, 6	0			
SBP; To w/in range or no change; n=27, 47, 10, 9, 6	6			
SBP; To high; n=27, 47, 10, 9, 6	0			
PR; To low; n=27, 47, 11, 9, 8	0			
PR; To w/in range or no change; n=27, 47, 11, 9, 8	8			
PR; To high; n=27, 47, 11, 9, 8	0			
Temp; To low; n=26, 46, 11, 10, 7	0			
Temp; To w/in range or no change; n=26, 46, 11, 10, 7	7			
Temp; To high; n=26, 46, 11, 10, 7	0			

Notes:

[12] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with worst-case hematology results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase

End point title	Number of participants with worst-case hematology results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase <sup>[13]</sup>
-----------------	---

End point description:

Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (Hct) (low: 0.201 and high: >0.599 proportion of red blood cells in blood); hemoglobin (Hgb) (low: <80 and high: >180 grams per liter [g/L]), lymphocytes (Lymph) (low: <0.8x10<sup>9</sup> cells/L); neutrophil (Neut) count (low: <1.5x10<sup>9</sup> cells/L); platelet (plat) count (low: <100x10<sup>9</sup> cells/L and high: >550x10<sup>9</sup> cells/L); leukocytes (leuko) (low: <3x10<sup>9</sup> cells/L and high: >20x10<sup>9</sup> cells/L) and eosinophils (Eos) (high: >=1x10<sup>9</sup> cells/L). Participants were counted in the worst-case category that their value changed to (low, w/in range or no change, or high), unless there was no change in their category. Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 10

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[14]</sup>	48 <sup>[15]</sup>	11 <sup>[16]</sup>	10 <sup>[17]</sup>
Units: Participants				
Eos;w/in range or no change; n=25,45,9,8,7	24	44	9	8
Eos; To high; n=25,45,9,8,7	1	1	0	0
Hct; To low; n=24,43,7,6,7	0	0	0	0
Hct; To w/in range or no change; n=24,43,7,6,7	24	43	7	6
Hct; To high; n=24,43,7,6,7	0	0	0	0
Hgb; To low; n=24,45,5,7,7	0	0	1	1
Hgb; To w/in range or no change; n=24,45,5,7,7	24	45	4	6
Hgb; To high; n=24,45,5,7,7	0	0	0	0
Leuko; To low; n=27,43,8,9,6	0	2	0	1
Leuko; To w/in range or no change; n=27,43,8,9,6	27	41	8	8
Leuko; To high; n=27,43,8,9,6	0	0	0	0
Lymph; To low; n=26,45,8,8,8	1	6	1	3
Lymph; To w/in range or no change; n=26,45,8,8,8	25	39	7	5
Neut; To low; n=26,42,7,9,8	0	2	0	0
Neut; To w/in range or no change; n=26,42,7,9,8	26	40	7	9
Plat; To low; n=26,43,9,8,6	0	0	0	0
Plat; To w/in range or no change; n=26,43,9,8,6	25	41	9	7
Plat; To high; n=26,43,9,8,6	1	2	0	1

Notes:

[14] - Safety Population

[15] - Safety Population

[16] - Safety Population

[17] - Safety Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[18]</sup>			
Units: Participants				
Eos;w/in range or no change; n=25,45,9,8,7	7			
Eos; To high; n=25,45,9,8,7	0			
Hct; To low; n=24,43,7,6,7	0			
Hct; To w/in range or no change; n=24,43,7,6,7	7			
Hct; To high; n=24,43,7,6,7	0			
Hgb; To low; n=24,45,5,7,7	0			
Hgb; To w/in range or no change; n=24,45,5,7,7	7			
Hgb; To high; n=24,45,5,7,7	0			
Leuko; To low; n=27,43,8,9,6	0			
Leuko; To w/in range or no change; n=27,43,8,9,6	6			
Leuko; To high; n=27,43,8,9,6	0			

Lymph; To low; n=26,45,8,8,8	2			
Lymph; To w/in range or no change; n=26,45,8,8,8	6			
Neut; To low; n=26,42,7,9,8	0			
Neut; To w/in range or no change; n=26,42,7,9,8	8			
Plat; To low; n=26,43,9,8,6	0			
Plat; To w/in range or no change; n=26,43,9,8,6	6			
Plat; To high; n=26,43,9,8,6	0			

Notes:

[18] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with worst-case clinical chemistry results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase

End point title	Number of participants with worst-case clinical chemistry results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase <sup>[19]</sup>
-----------------	---

End point description:

Blood samples were collected for assessment of clinical chemistry parameters. Clinical concern range: albumin (Alb) (low: <30 and high: >55 g/L), calcium (Ca) (low: 2 and high: 2.75 millimoles per liter [mmol/L]), urea (high: >10.5 mmol/L); creatinine (Creat) (high: change from Baseline >26 micromoles per liter [μmol/L]), glucose (Glu) (low: <3.5 and high: >7.9 mmol/L); estimated glomerular filtration rate (eGFR) (low: <60 milliliters per minute per 1.73 square meter [mL/min/1.73m<sup>2</sup>]); potassium (Pot) (low: <3 and high: >5.5 mmol/L); sodium (Sod) (low: <130 and high: >150 mmol/L); protein (Pro) (low: <50 and high: >85 g/L) and C-reactive protein (CRP) (high: >30 milligrams/L). Participants were counted in worst-case category that their value changed to (low, w/in range or no change, or high), unless there was no change in their category. Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 10

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[20]</sup>	48 <sup>[21]</sup>	11 <sup>[22]</sup>	10 <sup>[23]</sup>
Units: Participants				
Alb; To low; n=26,42,7,6,6	0	2	0	1
Alb; To w/in range or no change; n=26,42,7,6,6	26	40	7	5
Alb; To high; n=26,42,7,6,6	0	0	0	0
CRP; To w/in range or no change; n=26, 46,9,10,8	25	36	7	9
CRP; To high; n=26, 46,9,10,8	1	10	2	1
Cal; To low; n=26,45,7,4,7	1	0	0	1
Cal; To w/in range or no change; n=26,45,7,4,7	25	45	7	3
Cal; To high; n=26,45,7,4,7	0	0	0	0



eGFR; To low; n=24,46,6,9,7	1	1	0	1
eGFR; To w/in range or no change; n=24,46,6,9,7	23	45	6	8
Glu; To low; n=26,45,5,8,7	1	1	0	0
Glu; To w/in range or no change; n=26,45,5,8,7	25	43	5	8
Glu; To high; n=26,45,5,8,7	0	1	0	0
Pot; To low; n=27,44,10,7,8	0	1	0	0
Pot; To w/in range or no change; n=27,44,10,7,8	27	43	10	7
Pot; To high; n=27,44,10,7,8	0	0	0	0
Pro; To low; n=26,43,7,5,7	0	0	0	0
Pro To w/in range or no change; n=26,43,7,5,7	26	41	7	5
Pro; To high; n=26,43,7,5,7	0	2	0	0
Sod; To low; n=25,45,10,8,8	0	0	0	0
Sod; To w/in range or no change; n=25,45,10,8,8	25	45	10	8
Sod; To high; n=25,45,10,8,8	0	0	0	0
Urea; To w/in range or no change; n=26,45,5,6,7	26	45	5	6
Urea; To high; n=26,45,5,6,7	0	0	0	0
Creat; To w/in range or no change; n=27,44,9,6,7	27	44	9	6
Creat; To high; n=27,44,9,6,7	0	0	0	0

Notes:

[20] - Safety Population

[21] - Safety Population

[22] - Safety Population

[23] - Safety Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[24]</sup>			
Units: Participants				
Alb; To low; n=26,42,7,6,6	0			
Alb; To w/in range or no change; n=26,42,7,6,6	6			
Alb; To high; n=26,42,7,6,6	0			
CRP; To w/in range or no change; n=26, 46,9,10,8	8			
CRP; To high; n=26, 46,9,10,8	0			
Cal; To low; n=26,45,7,4,7	0			
Cal; To w/in range or no change; n=26,45,7,4,7	7			
Cal; To high; n=26,45,7,4,7	0			
eGFR; To low; n=24,46,6,9,7	0			
eGFR; To w/in range or no change; n=24,46,6,9,7	7			
Glu; To low; n=26,45,5,8,7	0			
Glu; To w/in range or no change; n=26,45,5,8,7	7			
Glu; To high; n=26,45,5,8,7	0			
Pot; To low; n=27,44,10,7,8	0			

Pot; To w/in range or no change; n=27,44,10,7,8	8			
Pot; To high; n=27,44,10,7,8	0			
Pro; To low; n=26,43,7,5,7	0			
Pro To w/in range or no change; n=26,43,7,5,7	7			
Pro; To high; n=26,43,7,5,7	0			
Sod; To low; n=25,45,10,8,8	0			
Sod; To w/in range or no change; n=25,45,10,8,8	8			
Sod; To high; n=25,45,10,8,8	0			
Urea; To w/in range or no change; n=26,45,5,6,7	7			
Urea; To high; n=26,45,5,6,7	0			
Creat; To w/in range or no change; n=27,44,9,6,7	7			
Creat; To high; n=27,44,9,6,7	0			

Notes:

[24] - Safety Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with worst-case liver function results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase

End point title	Number of participants with worst-case liver function results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase <sup>[25]</sup>
-----------------	---

End point description:

Blood samples were collected for the assessment of liver function parameters. The clinical concern range for liver function parameters were: alanine aminotransferase (ALT) (high:  $\geq 2$  times upper limit of normal [ULN]); aspartate aminotransferase (AST) (high:  $\geq 2$  times ULN); alkaline phosphatase (ALP) (high:  $\geq 2$  times ULN) and bilirubin (Bil) (high:  $\geq 1.5$  times ULN). Participants were counted in the worst-case category that their value changed to (within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To within (w/in) Range or No Change category". Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 10

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[26]</sup>	48 <sup>[27]</sup>	11 <sup>[28]</sup>	10 <sup>[29]</sup>
Units: Participants				
ALT; To low; n=26,44,7,7,8	0	0	0	0
ALT; To w/in range or no change; n=26,44,7,7,8	25	42	7	7
ALT; To high; n=26,44,7,7,8	1	2	0	0
AST; To low; n=26,45,7,8,7	0	0	0	0

AST; To w/in range or no change; n=26,45,7,8,7	26	44	7	8
AST; To high; n=26,45,7,8,7	0	1	0	0
ALP; To low; n=27,44,9,9,8	0	0	0	0
ALP; To w/in range or no change; n=27,44,9,9,8	27	44	9	9
ALP; To high; n=27,44,9,9,8	0	0	0	0
Bil; To low; n=25,45,9,8,8	0	0	0	0
Bil; To w/in range or no change; n=25,45,9,8,8	25	45	9	8
Bil; To high; n=25,45,9,8,8	0	0	0	0

Notes:

[26] - Safety Population

[27] - Safety Population

[28] - Safety Population

[29] - Safety Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[30]</sup>			
Units: Participants				
ALT; To low; n=26,44,7,7,8	0			
ALT; To w/in range or no change; n=26,44,7,7,8	8			
ALT; To high; n=26,44,7,7,8	0			
AST; To low; n=26,45,7,8,7	0			
AST; To w/in range or no change; n=26,45,7,8,7	7			
AST; To high; n=26,45,7,8,7	0			
ALP; To low; n=27,44,9,9,8	0			
ALP; To w/in range or no change; n=27,44,9,9,8	8			
ALP; To high; n=27,44,9,9,8	0			
Bil; To low; n=25,45,9,8,8	0			
Bil; To w/in range or no change; n=25,45,9,8,8	8			
Bil; To high; n=25,45,9,8,8	0			

Notes:

[30] - Safety Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of participants with worst-case urinalysis results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase

End point title	Number of participants with worst-case urinalysis results by PCI criteria post-Baseline relative to Baseline-Double-Blind Induction Phase <sup>[31]</sup>
-----------------	---

End point description:

Urine samples were collected for the assessment of urine parameters by dipstick and microscopy. The dipstick test gives results in a semi-quantitative manner, and results can be read as Trace, 1+, 2+ indicating proportional concentrations in the urine sample. The clinical concern range for urine parameters were: Bil (high: >1+), glu (high: >1+); ketone (ket) (high: >2+); leuko (high: >1+); leukocyte esterase (LE); nitrite (nit) (high: positive); occult blood (OB) (high: >1+); potential of

hydrogen (pH) (low: <4.6 and high: >8); prot (high:>1+); erythrocytes (erythro) (high: >3 cells per high power field [hpf]); specific gravity (sp gra) (low: <1.001 and high: >1.035) and urobilinogen (uro) (high: >1 mg/deciliter). Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Primary
End point timeframe:	
Up to Week 10	

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[32]</sup>	48 <sup>[33]</sup>	11 <sup>[34]</sup>	10 <sup>[35]</sup>
Units: Participants				
Bil; To w/in range or no change; n=27,47,10,9,8	27	46	10	9
Bil; To high; n=27,47,10,9,8	0	1	0	0
Glu; To w/in range or no change; n=27,47,10,10,8	27	47	10	10
Glu; To high; n=27,47,10,10,8	0	0	0	0
Ket; To w/in range or no change; n=27,47,10,8,8	25	47	10	7
Ket; To high; n=27,47,10,8,8	2	0	0	1
LE; To w/in range or no change; n=26,45,9,8,8	25	37	9	8
LE; To high; n=26,45,9,8,8	1	8	0	0
Nit; To w/in range or no change; n=27,47,10,10,8	27	44	9	8
Nit; To high; n=27,47,10,10,8	0	3	1	2
OB; To w/in range or no change; n=26,46,9,10,8	24	42	9	10
OB; To high; n=26,46,9,10,8	2	4	0	0
pH; To low; n=27,46,9,10,7	0	0	0	0
pH; To w/in range or no change; n=27,46,9,10,7	26	46	9	10
pH; To high; n=27,46,9,10,7	1	0	0	0
Prot; To w/in range or no change; n=25,47,10,9,8	24	43	10	9
Prot; To high; n=25,47,10,9,8	1	4	0	0
Uro; To w/in range or no change; n=27,47,10,8,8	27	47	10	8
Uro; To high; n=27,47,10,8,8	0	0	0	0
Leuko; To w/in range or no change; n=9,18,2,3,1	8	15	1	3
Leuko; To high; n=9,18,2,3,1	1	3	1	0
Erythro; To w/in range or no change; n=9,18,2,3,1	9	16	1	3
Erythro; To high; n=9,18,2,3,1	0	2	1	0
Sp gra; To low; n=25,47,5,7,8	0	0	0	0
Sp gra; To w/in range or no change; n=25,47,5,7,8	21	44	5	7
Sp gra; To high; n=25,47,5,7,8	4	3	0	0

Notes:

[32] - Safety Population

[33] - Safety Population

[34] - Safety Population

[35] - Safety Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[36]</sup>			
Units: Participants				
Bil; To w/in range or no change; n=27,47,10,9,8	8			
Bil; To high; n=27,47,10,9,8	0			
Glu; To w/in range or no change; n=27,47,10,10,8	8			
Glu; To high; n=27,47,10,10,8	0			
Ket; To w/in range or no change; n=27,47,10,8,8	8			
Ket; To high; n=27,47,10,8,8	0			
LE; To w/in range or no change; n=26,45,9,8,8	8			
LE; To high; n=26,45,9,8,8	0			
Nit; To w/in range or no change; n=27,47,10,10,8	8			
Nit; To high; n=27,47,10,10,8	0			
OB; To w/in range or no change; n=26,46,9,10,8	8			
OB; To high; n=26,46,9,10,8	0			
pH; To low; n=27,46,9,10,7	0			
pH; To w/in range or no change; n=27,46,9,10,7	7			
pH; To high; n=27,46,9,10,7	0			
Prot; To w/in range or no change; n=25,47,10,9,8	8			
Prot; To high; n=25,47,10,9,8	0			
Uro; To w/in range or no change; n=27,47,10,8,8	8			
Uro; To high; n=27,47,10,8,8	0			
Leuko; To w/in range or no change; n=9,18,2,3,1	1			
Leuko; To high; n=9,18,2,3,1	0			
Erythro; To w/in range or no change; n=9,18,2,3,1	1			
Erythro; To high; n=9,18,2,3,1	0			
Sp gra; To low; n=25,47,5,7,8	0			
Sp gra; To w/in range or no change; n=25,47,5,7,8	8			
Sp gra; To high; n=25,47,5,7,8	0			

Notes:

[36] - Safety Population

## Statistical analyses

No statistical analyses for this end point

**Primary: Number of participants with maximum corrected QT (QTc) values post-Baseline relative to Baseline-Double-Blind Induction Phase**

End point title	Number of participants with maximum corrected QT (QTc) values post-Baseline relative to Baseline-Double-Blind Induction Phase <sup>[37]</sup>
End point description: Twelve lead electrocardiograms (ECGs) were obtained using an ECG machine that automatically calculated the QT interval corrected for heart rate according to either Bazett's formula (QTcB) or Fridericia's formula (QTcF). The clinical concern range for the QTcB and QTcF intervals was upper: >450 milliseconds. Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)	
End point type	Primary
End point timeframe: Up to Week 10	

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[38]</sup>	48 <sup>[39]</sup>	11 <sup>[40]</sup>	10 <sup>[41]</sup>
Units: Participants				
QTcB; No change or decrease to <450; n=26,44,8,9,7	22	41	6	7
QTcB; Any increase to >=450; n=26,44,8,9,7	4	3	2	2
QTcF; No change or decrease to <450; n=26,46,7,9,7	26	45	7	8
QTcF; Any increase to >=450; n=26,46,7,9,7	0	1	0	1

Notes:

[38] - Safety Population

[39] - Safety Population

[40] - Safety Population

[41] - Safety Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[42]</sup>			
Units: Participants				
QTcB; No change or decrease to <450; n=26,44,8,9,7	7			
QTcB; Any increase to >=450; n=26,44,8,9,7	0			
QTcF; No change or decrease to <450; n=26,46,7,9,7	7			
QTcF; Any increase to >=450; n=26,46,7,9,7	0			

Notes:

[42] - Safety Population

**Statistical analyses**

No statistical analyses for this end point

### Primary: Change from Baseline in Complete 4-domain Mayo score at Week 10

End point title	Change from Baseline in Complete 4-domain Mayo score at Week 10 <sup>[43]</sup>
-----------------	---

End point description:

Complete 4-domain Mayo Score is a 12-point scoring system where disease is evaluated based on 4 components: stool frequency, rectal bleeding, physician global assessment (PGA) and endoscopic appearance (with mild friability associated with an endoscopic score of 1). Score for each component ranges from 0 (normal/none) to 3 (severe). Complete Mayo score is calculated as sum of 4 components and ranges from 0 to 12. Higher scores indicate greater disease severity. Baseline value is latest pre-dose assessment with a non-missing value from Double-Blind Induction study phase. Change from Baseline=value at specified time point minus Baseline value. Intent-To-Treat-Exposed (ITTE) Population= all enrolled participants who received at least one dose of study treatment, and who had at least one valid post dose assessment. Only those participants with data available at the specified time points were analyzed.

End point type	Primary
----------------	---------

End point timeframe:

Baseline and Week 10

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[44]</sup>	36 <sup>[45]</sup>	4 <sup>[46]</sup>	2 <sup>[47]</sup>
Units: Scores on a scale				
arithmetic mean (standard error)	-1.5 (± 0.45)	-1.4 (± 0.36)	-0.3 (± 0.48)	-1.0 (± 2.00)

Notes:

[44] - ITTE Population

[45] - ITTE Population

[46] - ITTE Population

[47] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[48]</sup>			
Units: Scores on a scale				
arithmetic mean (standard error)	-2.3 (± 0.33)			

Notes:

[48] - ITTE Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with AEs and SAEs-Double-Blind Extended Treatment Phase

End point title	Number of participants with AEs and SAEs-Double-Blind Extended Treatment Phase
-----------------	--

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the

use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect or other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. Safety Extended Treatment Population comprised of all participants who received at least one dose of study treatment in the Extended Treatment Phase

End point type	Secondary
End point timeframe:	
Week 14 to 30	

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5 <sup>[49]</sup>	8 <sup>[50]</sup>		
Units: Participants				
AEs	1	3		
SAEs	0	1		

Notes:

[49] - Safety Extended Treatment Population

[50] - Safety Extended Treatment Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with worst-case vital signs results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase

End point title	Number of participants with worst-case vital signs results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase
-----------------	---

End point description:

Vital signs were measured in a seated or semi-supine position after 5 minutes rest. The clinical concern range for vital signs were: SBP (lower: <85 and upper: > 160 mmHg); DBP (lower: <45 mmHg and upper: >100 mmHg); PR (lower: <40 and upper: >110 bpm) and Temp (lower: <35 and upper: >38 degree Celsius). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%.

End point type	Secondary
End point timeframe:	
Week 14 to 30	

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5 <sup>[51]</sup>	8 <sup>[52]</sup>		
Units: Participants				
DBP; To low	0	0		
DBP; To w/in range or no change	5	8		



DBP; To high	0	0		
SBP; To low	0	0		
SBP; To w/in range or no change	5	8		
SBP; To high	0	0		
PR; To low	0	0		
PR; To w/in range or no change	5	8		
PR; To high	0	0		
Temp; To low	0	0		
Temp; To w/in range or no change	5	8		
Temp; To high	0	0		

Notes:

[51] - Safety Extended Treatment Population

[52] - Safety Extended Treatment Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with worst-case hematology results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase

End point title	Number of participants with worst-case hematology results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase
-----------------	--

End point description:

Blood samples were collected for the assessment of hematology parameters. Clinical concern range for the parameters were: Hct (low: 0.201 and high: >0.599 proportion of red blood cells in blood); Hgb (low: <80 and high: >180 g/L), Lymph (low: <0.8x10<sup>9</sup> cells/L); Neut count (low: <1.5x10<sup>9</sup> cells/L); plat count (low: <100x10<sup>9</sup> cells/L and high: >550x10<sup>9</sup> cells/L); leuko (low: <3x10<sup>9</sup> cells/L and high: >20x10<sup>9</sup>cells/L) and Eos (high: >=1x10<sup>9</sup> cells/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 to 30

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5 <sup>[53]</sup>	8 <sup>[54]</sup>		
Units: Participants				
Eos;To w/in range or no change; n=4,8	4	8		
Eos; To high; n=4,8	0	0		
Hct; To low; n=5,8	0	0		
Hct; To w/in range or no change; n=5,8	5	8		
Hct; To high; n=5,8	0	0		
Hgb; To low; n=5,8	0	0		
Hgb; To w/in range or no change; n=5,8	5	8		
Hgb; To high; n=5,8	0	0		
Leuko; To low; n=5,8	0	0		

Leuko; To w/in range or no change; n=5,8	5	8		
Leuko; To high; n=5,8	0	0		
Lymph; To low; n=5,8	0	2		
Lymph; To w/in range or no change; n=5,8	5	6		
Neut; To low; n=5,8	0	0		
Neut; To w/in range or no change; n=5,8	5	8		
Plat; To low; n=5,8	0	0		
Plat; To w/in range or no change; n=5,8	5	6		
Plat; To high; n=5,8	0	2		

Notes:

[53] - Safety Extended Treatment Population

[54] - Safety Extended Treatment Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with worst-case clinical chemistry results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase

End point title	Number of participants with worst-case clinical chemistry results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase
-----------------	--

End point description:

Blood samples were collected for the assessment of clinical chemistry parameters. Clinical concern range for the parameters were: Alb (low: <30 and high: >55 g/L), C (low: 2 and high: 2.75 mmol/L), urea (high: >10.5 mmol/L); Creat (high: change from Baseline >26 µmol/L), Glu (low: <3.5 and high: >7.9 mmol/L); eGFR (low: <60 mL/min/1.73m<sup>2</sup>); Pot low: <3 and high: >5.5 mmol/L; Sod (low: <130 and high: >150 mmol/L); Pro (low: <50 and high: >85 g/L) and CRP (high: >30 milligrams/L). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category". Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 to 30

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5 <sup>[55]</sup>	8 <sup>[56]</sup>		
Units: Participants				
Alb; To low; n=5,8	0	1		
Alb; To w/in range or no change; n=5,8	5	7		
Alb; To high; n=5,8	0	0		
CRP; To w/in range or no change; n=5,8	5	6		
CRP; To high; n=5,8	0	2		
Cal; To low; n=5,8	0	0		
Cal; To w/in range or no change; n=5,8	5	8		
Cal; To high; n=5,8	0	0		

eGFR; To low; n=4,8	0	1		
eGFR; To w/in range or no change; n=4,8	4	7		
Glu; To low; n=5,8	0	0		
Glu; To w/in range or no change; n=5,8	5	8		
Glu; To high; n=5,8	0	0		
Pot; To low; n=4,8	0	0		
Pot; To w/in range or no change; n=4,8	4	8		
Pot; To high; n=4,8	0	0		
Pro; To low; n=5,8	0	0		
Pro To w/in range or no change; n=5,8	5	8		
Pro; To high; n=5,8	0	0		
Sod; To low; n=4,8	0	0		
Sod; To w/in range or no change; n=4,8	4	8		
Sod; To high; n=4,8	0	0		
Urea; To w/in range or no change; n=5,8	5	8		
Urea; To high; n=5,8	0	0		
Creat; To w/in range or no change; n=5,8	5	8		
Creat; To high; n=5,8	0	0		

Notes:

[55] - Safety Extended Treatment Population

[56] - Safety Extended Treatment Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with worst-case liver function results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase

End point title	Number of participants with worst-case liver function results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase
-----------------	--

End point description:

Blood samples were collected for the assessment of liver function parameters. The clinical concern range for liver function parameters were: ALT (high:  $\geq 2$  times ULN); AST (high:  $\geq 2$  times ULN); ALP (high:  $\geq 2$  times ULN) and Bil (high:  $\geq 1.5$  times ULN). Participants were counted in the worst-case category that their value changed to (low, within range or no change, or high), unless there was no change in their category. Participants whose value category was unchanged (e.g. High to High), or whose value became within range, were recorded in the "To w/in Range or No Change category".

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 to 30

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5 <sup>[57]</sup>	8 <sup>[58]</sup>		
Units: Participants				
ALT; To low	0	0		
ALT; To w/in range or no change	5	8		
ALT; To high	0	0		

AST; To low	0	0		
AST; To w/in range or no change	5	8		
AST; To high	0	0		
ALP; To low	0	0		
ALP; To w/in range or no change	5	8		
ALP; To high	0	0		
Bil; To low	0	0		
Bil; To w/in range or no change	5	8		
Bil; To high	0	0		

Notes:

[57] - Safety Extended Treatment Population

[58] - Safety Extended Treatment Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with worst-case urinalysis results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase

End point title	Number of participants with worst-case urinalysis results by PCI criteria post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase
-----------------	--

End point description:

Urine samples were collected for the assessment of urine parameters by dipstick and microscopy. The dipstick test gives results in a semi-quantitative manner, and results can be read as Trace, 1+, 2+ indicating proportional concentrations in the urine sample. The clinical concern range for urine parameters were: Bil (high: >1+), glu (high: >1+); ket (high: >2+); leuko (high: >1+); LE; nit (high: positive); OB (high: >1+); pH (low: <4.6 and high: >8); prot (high:>1+); erythro (high: >3 cells per hpf); sp gra (low: <1.001 and high: >1.035) and uro (high: >1 mg/deciliter). Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 to 30

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	5 <sup>[59]</sup>	8 <sup>[60]</sup>		
Units: Participants				
Bil; To w/in range or no change; n=5,8	5	8		
Bil; To high; n=5,8	0	0		
Glu; To w/in range or no change; n=5,8	5	8		
Glu; To high; n=5,8	0	0		
Ket; To w/in range or no change; n=5,8	5	8		
Ket; To high; n=5,8	0	0		
LE; To w/in range or no change; n=5,8	3	8		
LE; To high; n=5,8	2	0		
Nit; To w/in range or no change; n=5,8	5	7		
Nit; To high; n=5,8	0	1		
OB; To w/in range or no change; n=5,8	4	7		
OB; To high; n=5,8	1	1		
pH; To low; n=5,8	0	0		

pH; To w/in range or no change; n=5,8	5	8		
pH; To high; n=5,8	0	0		
Prot; To w/in range or no change; n=5,8	4	8		
Prot; To high; n=5,8	1	0		
Uro; To w/in range or no change; n=5,8	5	8		
Uro; To high; n=5,8	0	0		
Leuko; To w/in range or no change; n=1,2	1	1		
Leuko; To high; n=1,2	0	1		
Erythro; To w/in range or no change; n=1,2	1	2		
Erythro; To high; n=1,2	0	0		
Sp gra; To low; n=5,8	0	0		
Sp gra; To w/in range or no change; n=5,8	4	6		
Sp gra; To high; n=5,8	1	2		

Notes:

[59] - Safety Extended Treatment Population

[60] - Safety Extended Treatment Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with maximum QTc values post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase

End point title	Number of participants with maximum QTc values post-Baseline relative to Baseline-Double-Blind Extended Treatment Phase
-----------------	---

End point description:

Twelve lead ECGs were obtained using an ECG machine that automatically calculated the QTcB and QTcF intervals. The clinical concern range for the QTcB and QTcF intervals was upper: >450 milliseconds. Only those participants with data available at the specified timepoints were analyzed (indicated by n=X in category titles)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 to 30

End point values	Placebo SC	GSK2831781 300 mg SC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	4 <sup>[61]</sup>	8 <sup>[62]</sup>		
Units: Participants				
QTcB; No change or decrease to <450; n=4,6	4	6		
QTcB; Any increase to >=450; n=4,6	0	0		
QTcF; No change or decrease to <450; n=3,6	3	6		
QTcF; Any increase to >=450; n=3,6	0	0		

Notes:

[61] - Safety Extended Treatment Population

[62] - Safety Extended Treatment Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adapted Mayo endoscopic score of 0 or 1 at Week 10-Double-Blind Induction Phase

End point title	Number of participants with adapted Mayo endoscopic score of 0 or 1 at Week 10-Double-Blind Induction Phase
-----------------	---

End point description:

The adapted Mayo clinical score consists of three components: stool frequency, rectal bleeding, and endoscopic appearance. The score for each component ranges from 0 (normal/none) to 3 (severe). The adapted Mayo endoscopic score of 0 indicates normal or inactive disease and 1 indicates mild disease (erythema, decreased vascular pattern). Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[63]</sup>	36 <sup>[64]</sup>	4 <sup>[65]</sup>	2 <sup>[66]</sup>
Units: Participants	4	3	0	0

Notes:

[63] - ITTE Population

[64] - ITTE Population

[65] - ITTE Population

[66] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[67]</sup>			
Units: Participants	0			

Notes:

[67] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with adapted Mayo clinical remission at Week 10-Double-Blind Induction Phase

End point title	Number of participants with adapted Mayo clinical remission at Week 10-Double-Blind Induction Phase
-----------------	---

---

**End point description:**

The adapted Mayo clinical score is based on the complete 4-domain Mayo clinical score, but without the PGA. It consists of three components: stool frequency, rectal bleeding, and mucosal endoscopic appearance. The score for each component ranges from 0 (normal/none) to 3 (severe). The total adapted Mayo score is calculated as the sum of all three components and ranges from 0 to 9. Higher scores indicate greater disease severity. Clinical remission is defined as adapted Mayo Clinical Score of  $\leq 2$  with no individual sub-score  $> 1$  and a rectal bleeding sub score of 0 with stool frequency sub score not greater than Baseline. Only those participants with data available at the specified time points were analyzed.

---

End point type	Secondary
End point timeframe:	
Week 10	

---

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[68]</sup>	36 <sup>[69]</sup>	4 <sup>[70]</sup>	2 <sup>[71]</sup>
Units: Participants	0	1	0	0

**Notes:**

[68] - ITTE Population

[69] - ITTE Population

[70] - ITTE Population

[71] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[72]</sup>			
Units: Participants	0			

**Notes:**

[72] - ITTE Population

---

**Statistical analyses**

No statistical analyses for this end point

---

**Secondary: Number of participants with adapted Mayo clinical response at Week 10-Double-Blind Induction Phase**

---

End point title	Number of participants with adapted Mayo clinical response at Week 10-Double-Blind Induction Phase
-----------------	--

---

**End point description:**

The adapted Mayo clinical score is based on the complete 4-domain Mayo clinical score, but without the PGA. It consists of three components: stool frequency, rectal bleeding, and mucosal endoscopic appearance. The score for each component ranges from 0 (normal/none) to 3 (severe). The total adapted Mayo score is calculated as the sum of all three components and ranges from 0 to 9. Higher scores indicate greater disease severity. Clinical response is defined as reduction in adapted Mayo clinical score  $\geq 3$  points from Baseline and  $\geq 30\%$  from Baseline and decrease in the rectal bleeding sub-score of  $\geq 1$  point from Baseline (or a score of 0 or 1). Only those participants with data available at the specified time points were analyzed.

---

End point type	Secondary
End point timeframe:	
Week 10	

---

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[73]</sup>	36 <sup>[74]</sup>	4 <sup>[75]</sup>	2 <sup>[76]</sup>
Units: Participants	5	6	0	1

Notes:

[73] - ITTE Population

[74] - ITTE Population

[75] - ITTE Population

[76] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[77]</sup>			
Units: Participants	0			

Notes:

[77] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with symptomatic remission at Week 10-Double-Blind Induction Phase

End point title	Number of participants with symptomatic remission at Week 10-Double-Blind Induction Phase
-----------------	---

End point description:

The Complete 4-domain Mayo Score is a 12-point scoring system where disease is evaluated based on the four components: stool frequency, rectal bleeding, PGA and endoscopic appearance (with mild friability associated with an endoscopic score of 1). Symptomatic remission is defined as a rectal bleeding subscore of 0, and a stool frequency subscore of  $\leq 1$ , with no worsening from Baseline. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[78]</sup>	36 <sup>[79]</sup>	4 <sup>[80]</sup>	2 <sup>[81]</sup>
Units: Participants	5	5	0	1

Notes:

[78] - ITTE Population

[79] - ITTE Population

[80] - ITTE Population



<b>End point values</b>	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[82]</sup>			
Units: Participants	1			

Notes:

[82] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in partial Mayo score over time-Double-Blind Induction Phase

End point title	Change from Baseline in partial Mayo score over time-Double-Blind Induction Phase
-----------------	---

End point description:

The partial Mayo clinical score is based on the complete 4-domain Mayo clinical score but without the endoscopy sub-score. It consists of three components: stool frequency, rectal bleeding, and PGA. The score for each component ranges from 0 (normal/none) to 3 (severe). The total partial Mayo score is calculated as the sum of all three components and ranges from 0 to 9. Higher scores indicate greater disease severity. Baseline value was the latest pre-dose assessment with a non-missing value from Double-Blind Induction study phase. Change from Baseline was calculated as value at specified time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Weeks 2, 4, 6, and 10

<b>End point values</b>	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[83]</sup>	48 <sup>[84]</sup>	11 <sup>[85]</sup>	10 <sup>[86]</sup>
Units: Scores on a scale				
arithmetic mean (standard error)				
Week 2; n=27, 47, 11, 10, 8	-0.8 (± 0.33)	-0.6 (± 0.22)	-1.0 (± 0.50)	0.5 (± 0.54)
Week 4; n=26, 46, 8, 8, 7	-1.0 (± 0.31)	-0.7 (± 0.28)	-1.4 (± 0.60)	-0.4 (± 0.18)
Week 6; n=24, 44, 8, 6, 8	-1.3 (± 0.40)	-0.8 (± 0.31)	-1.0 (± 0.53)	-0.8 (± 0.31)
Week 10; n=22, 39, 4, 4, 4	-1.1 (± 0.44)	-1.0 (± 0.32)	0.3 (± 0.48)	-1.0 (± 0.41)

Notes:

[83] - ITTE Population

[84] - ITTE Population

[85] - ITTE Population

[86] - ITTE Population

<b>End point values</b>	GSK2831781 45 mg IV			
-------------------------	------------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[87]</sup>			
Units: Scores on a scale				
arithmetic mean (standard error)				
Week 2; n=27, 47, 11, 10, 8	-1.3 (± 0.65)			
Week 4; n=26, 46, 8, 8, 7	-1.7 (± 0.52)			
Week 6; n=24, 44, 8, 6, 8	-2.6 (± 0.53)			
Week 10; n=22, 39, 4, 4, 4	-2.0 (± 0.41)			

Notes:

[87] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in adapted Mayo endoscopy score at Week 10-Double-Blind Induction Phase

End point title	Change from Baseline in adapted Mayo endoscopy score at Week 10-Double-Blind Induction Phase
-----------------	--

End point description:

The adapted Mayo clinical score is based on the complete 4-domain Mayo clinical score, but without the PGA. It consists of three components: stool frequency, rectal bleeding, and mucosal endoscopic appearance. The total adapted Mayo endoscopy score ranges from 0 (normal or inactive disease) to 3 (severe disease [spontaneous bleeding, ulceration]). Baseline value was the latest pre-dose assessment with a non-missing value from Double-Blind Induction study phase. Change from Baseline was calculated as value at specified time point minus Baseline value. Only those participants with data available at the specified time points were analyzed

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[88]</sup>	36 <sup>[89]</sup>	4 <sup>[90]</sup>	2 <sup>[91]</sup>
Units: Scores on a scale				
arithmetic mean (standard error)	-0.2 (± 0.14)	-0.1 (± 0.12)	0.0 (± 0.00)	0.5 (± 0.50)

Notes:

[88] - ITTE Population

[89] - ITTE Population

[90] - ITTE Population

[91] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[92]</sup>			
Units: Scores on a scale				
arithmetic mean (standard error)	-0.3 (± 0.33)			

Notes:

[92] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Ulcerative Colitis Endoscopic Index of Severity (UCEIS) at Week 10-Double-Blind Induction Phase

End point title	Change from Baseline in Ulcerative Colitis Endoscopic Index of Severity (UCEIS) at Week 10-Double-Blind Induction Phase
-----------------	---

End point description:

UCEIS was used as an additional tool to assess disease activity based on 3 sub-scales: endoscopic vascular pattern, bleeding, erosions and ulcerations. Individual sub-scale scores were vascular pattern (0=Normal, 1=Patchy loss, 2=Obliterated); bleeding (0=None, 1=Mucosal, 2=Luminal mild, 3=Luminal severe); erosions and ulcerations (0=None, 1=Erosions, 2=Superficial ulcer, 3=Deep ulcer). UCEIS total score was calculated as the sum of all 3 sub-scale scores and ranges from 0 to 8, with higher scores indicating more severe disease. Baseline value was the latest pre-dose assessment with a non-missing value from Double-Blind Induction study phase. Change from Baseline was calculated as value at specified time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[93]</sup>	36 <sup>[94]</sup>	4 <sup>[95]</sup>	2 <sup>[96]</sup>
Units: Scores on a scale				
arithmetic mean (standard error)	-0.1 (± 0.41)	-0.0 (± 0.25)	0.5 (± 0.65)	1.0 (± 0.00)

Notes:

[93] - ITTE Population

[94] - ITTE Population

[95] - ITTE Population

[96] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[97]</sup>			
Units: Scores on a scale				
arithmetic mean (standard error)	0.0 (± 0.58)			

Notes:

[97] - ITTE Population

## Statistical analyses

**Secondary: Number of responders for Robarts Histopathology Index (RHI) remission at Week 10-Double-Blind Induction Phase**

End point title	Number of responders for Robarts Histopathology Index (RHI) remission at Week 10-Double-Blind Induction Phase
-----------------	---

## End point description:

RHI was assessed by central reading of gut pinch biopsies. The RHI Score is a continuous score, ranging from 0-33 with higher scores indicating more severe disease. RHI Remission is defined as an RHI score  $\leq 6$ . Responders were defined as number of participants with RHI score  $\leq 6$ . Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

## End point timeframe:

Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[98]</sup>	36 <sup>[99]</sup>	4 <sup>[100]</sup>	2 <sup>[101]</sup>
Units: Participants	4	5	0	0

## Notes:

[98] - ITTE Population

[99] - ITTE Population

[100] - ITTE Population

[101] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[102]</sup>			
Units: Participants	0			

## Notes:

[102] - ITTE Population

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of responders for Nancy Histological Index remission at Week 10-Double-Blind Induction Phase**

End point title	Number of responders for Nancy Histological Index remission at Week 10-Double-Blind Induction Phase
-----------------	---

## End point description:

Nancy Histological Index was assessed by central reading of gut pinch biopsies. Key domains for scoring of the indices include chronic inflammatory infiltrate, neutrophils in the epithelium, lamina propria neutrophils, erosion and ulceration scored from 0 to 3 and multiplied by a weighting factor. The total Nancy Histological Index score is calculated by summing the weighted scores of the histological items, with total scores ranging from 0 (no disease activity) to 33 (severe disease activity). Nancy Index Remission was defined as a grade of 0 or 1. Responders were defined as number of participants with Nancy Index score of 0 or 1. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[103]</sup>	36 <sup>[104]</sup>	4 <sup>[105]</sup>	2 <sup>[106]</sup>
Units: Participants	4	4	0	0

Notes:

[103] - ITTE Population

[104] - ITTE Population

[105] - ITTE Population

[106] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[107]</sup>			
Units: Participants	0			

Notes:

[107] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of responders for Geboes Histological Index remission at Week 10-Double-Blind Induction Phase

End point title	Number of responders for Geboes Histological Index remission at Week 10-Double-Blind Induction Phase
-----------------	--

End point description:

The Geboes Index is divided in 6 grades: architectural changes [grade 0], chronic inflammatory infiltrate [grade 1], lamina propria neutrophils and eosinophils [grade 2], neutrophils in epithelium [grade 3], crypt destruction [grade 4] and erosions or ulcerations [grade 5]. The subscores for grade 0 to 4 ranges from 0 (none/no abnormality) to 3 (marked increase/severe abnormality) and for grade 5 ranges from 0 (No erosion, ulceration, or granulation tissue) to 4 (Ulcer or granulation tissue). The overall Geboes score is derived by summing the subscores of the grades and ranges from 0 to 22, with higher scores indicating greater disease severity. Geboes Histological Remission was defined as a Geboes score <2. Responders were defined as number of participants with Geboes score <2. Only those participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21 <sup>[108]</sup>	36 <sup>[109]</sup>	4 <sup>[110]</sup>	2 <sup>[111]</sup>
Units: Participants	1	1	0	0

Notes:

[108] - ITTE Population

[109] - ITTE Population

[110] - ITTE Population

[111] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	3 <sup>[112]</sup>			
Units: Participants	0			

Notes:

[112] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in serum CRP level over time-Double-Blind Induction Phase

End point title	Change from Baseline in serum CRP level over time-Double-Blind Induction Phase
-----------------	--

End point description:

Serum samples were collected at indicated time points to measure CRP levels. Baseline value was the latest pre-dose assessment with a non-missing value from Double-Blind Induction study phase. Change from Baseline was calculated as value at specified time point minus Baseline value. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Weeks 2, 4, 6, and 10

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[113]</sup>	48 <sup>[114]</sup>	11 <sup>[115]</sup>	10 <sup>[116]</sup>
Units: Milligrams per liter				
arithmetic mean (standard deviation)				
Week 2; n=27, 47, 11, 10, 8	-1.52 (± 8.508)	1.01 (± 8.004)	8.23 (± 16.881)	25.14 (± 62.574)
Week 4; n=26,45,7,7,7	-3.38 (± 8.188)	6.73 (± 21.625)	0.74 (± 3.376)	26.23 (± 62.003)
Week 6; n=24,45,8,6,8	-3.09 (± 6.748)	4.45 (± 13.491)	2.34 (± 7.016)	12.20 (± 15.566)
Week 10; n=22,39,4,4,4	2.89 (± 9.460)	8.99 (± 21.549)	8.40 (± 8.102)	6.75 (± 13.749)

Notes:

[113] - ITTE Population

[114] - ITTE Population

[115] - ITTE Population

[116] - ITTE Population

End point values	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[117]</sup>			
Units: Milligrams per liter				
arithmetic mean (standard deviation)				
Week 2; n=27, 47, 11, 10, 8	-7.71 (± 14.627)			
Week 4; n=26,45,7,7,7	-9.41 (± 18.059)			
Week 6; n=24,45,8,6,8	-8.16 (± 18.602)			
Week 10; n=22,39,4,4,4	-8.48 (± 20.407)			

Notes:

[117] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Ratio to Baseline in fecal calprotectin over time-Double-Blind Induction Phase

End point title	Ratio to Baseline in fecal calprotectin over time-Double-Blind Induction Phase
End point description:	
Fecal samples were collected at indicated time points to measure fecal calprotectin. Baseline value was the latest pre-dose assessment with a non-missing value from Double-Blind Induction study phase. Ratio to Baseline is the value at specified time point divided by Baseline value. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). 99999 indicates data was not available as insufficient participants were analyzed.	
End point type	Secondary
End point timeframe:	
Baseline and Weeks 2, 4, 6, and 10	

End point values	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[118]</sup>	48 <sup>[119]</sup>	11 <sup>[120]</sup>	10 <sup>[121]</sup>
Units: Ratio				
geometric mean (geometric coefficient of variation)				
Week 2; n=25,40,9,9,6	1.28 (± 311.68)	0.90 (± 504.70)	0.57 (± 206.90)	2.05 (± 565.80)
Week 4; n=3,2,0,2,0	0.28 (± 296.27)	1.58 (± 794.82)	99999 (± 99999)	1.60 (± 55.72)

Week 6; n=23,37,7,6,7	0.99 (± 688.97)	0.99 (± 576.84)	4.01 (± 8478.60)	3.42 (± 477.17)
Week 10; n=20,31,3,3,4	1.68 (± 217.05)	1.27 (± 961.25)	3.82 (± 76.67)	8.50 (± 2110.12)

Notes:

[118] - ITTE Population

[119] - ITTE Population

[120] - ITTE Population

[121] - ITTE Population

<b>End point values</b>	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[122]</sup>			
Units: Ratio				
geometric mean (geometric coefficient of variation)				
Week 2; n=25,40,9,9,6	0.57 (± 200.43)			
Week 4; n=3,2,0,2,0	99999 (± 99999)			
Week 6; n=23,37,7,6,7	2.51 (± 182.31)			
Week 10; n=20,31,3,3,4	0.50 (± 251.03)			

Notes:

[122] - ITTE Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area under the concentration-time curve over the 1st dosing interval (AUC[0-tau]) for GSK2831781 following SC dosing in Double-Blind Extended Treatment Phase

End point title	Area under the concentration-time curve over the 1st dosing interval (AUC[0-tau]) for GSK2831781 following SC dosing in Double-Blind Extended Treatment Phase
-----------------	---

End point description:

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2831781. PK parameters were calculated using standard non-compartmental analysis. Pharmacokinetic Double-Blind Extended Population comprised of all participants in the Safety Extended Treatment Phase population who had at least 1 non-missing PK assessment in the Extended Treatment phase. Only those participants with data at more than two of the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 (pre-dose, 24, 72 and 168 hours post-dose); Week 18 (pre-dose and early withdrawal post-dose)



<b>End point values</b>	GSK2831781 300 mg SC			
Subject group type	Subject analysis set			
Number of subjects analysed	3 <sup>[123]</sup>			
Units: Hours*micrograms per milliliter				
geometric mean (geometric coefficient of variation)	24336.92 (± 23.797)			

Notes:

[123] - Pharmacokinetic Double-Blind Extended Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum concentration (C<sub>max</sub>) of GSK2831781 observed following 1st SC dosing in Double-Blind Extended Treatment Phase

End point title	Maximum concentration (C <sub>max</sub> ) of GSK2831781 observed following 1st SC dosing in Double-Blind Extended Treatment Phase
-----------------	---

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK2831781. PK parameters were calculated using standard non-compartmental analysis. Only those participants with data at more than two of the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 (pre-dose, 24, 72 and 168 hours post-dose); Week 18 (pre-dose and early withdrawal post-dose)

<b>End point values</b>	GSK2831781 300 mg SC			
Subject group type	Subject analysis set			
Number of subjects analysed	3 <sup>[124]</sup>			
Units: Micrograms per milliliter				
geometric mean (geometric coefficient of variation)	55.64 (± 13.374)			

Notes:

[124] - Pharmacokinetic Double-Blind Extended Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time at which the maximum concentration is observed (t<sub>max</sub>) for GSK2831781 following 1st SC dosing in Double-Blind Extended Treatment Phase

End point title	Time at which the maximum concentration is observed (t <sub>max</sub> ) for GSK2831781 following 1st SC dosing in Double-Blind Extended Treatment Phase
-----------------	---

End point description:

Blood samples were collected at indicated time points for PK analysis of GSK2831781. PK parameters were calculated using standard non-compartmental analysis. Only those participants with data at more than two of the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 (pre-dose, 24, 72 and 168 hours post-dose); Week 18 (pre-dose and early withdrawal post-dose)

<b>End point values</b>	GSK2831781 300 mg SC			
Subject group type	Subject analysis set			
Number of subjects analysed	3 <sup>[125]</sup>			
Units: Hours				
median (full range (min-max))	72.03 (24.3 to 170.0)			

Notes:

[125] - Pharmacokinetic Double-Blind Extended Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with positive anti-drug antibodies at each visit-Double-Blind Induction Phase

End point title	Number of participants with positive anti-drug antibodies at each visit-Double-Blind Induction Phase
-----------------	--

End point description:

Serum samples were assessed for the presence of anti-drug antibodies using a tiered approach. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'confirmed positive'. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). 99999 indicates data was not available as insufficient participants were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 6, and 10

<b>End point values</b>	Placebo IV	GSK2831781 450 mg IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27 <sup>[126]</sup>	48 <sup>[127]</sup>	11 <sup>[128]</sup>	10 <sup>[129]</sup>
Units: Participants				
Baseline; n=27,48,11,10,8	0	0	0	0
Week 2; n=27,47,11,10,8	0	0	0	0
Week 4; n=25,46,7,7,7	0	0	0	0
Week 6; n=1,3,3,0,3	0	0	0	99999
Week 10; n=22,39,4,4,4	0	0	0	0

Notes:

[126] - Safety Population

[127] - Safety Population

[128] - Safety Population

<b>End point values</b>	GSK2831781 45 mg IV			
Subject group type	Reporting group			
Number of subjects analysed	8 <sup>[130]</sup>			
Units: Participants				
Baseline; n=27,48,11,10,8	0			
Week 2; n=27,47,11,10,8	0			
Week 4; n=25,46,7,7,7	0			
Week 6; n=1,3,3,0,3	0			
Week 10; n=22,39,4,4,4	0			

Notes:

[130] - Safety Population

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to Week 12 (participants who entered OL induction phase) or Week 14 (participants who entered double-blind [DB] ETP) for DB induction phase, from Week 14 to 30 for DB ETP, from Week 12 to 22 for OL induction phase and from Week 22 to 42 for OL ETP

Adverse event reporting additional description:

Non-SAEs and SAEs were collected in Safety Population for Double-blind induction phase, Safety ETP for double-blind ETP, Safety OL induction and Safety OL ETP for OL induction phase and OL ETP respectively.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Placebo IV
-----------------------	------------

Reporting group description:

Participants were administered placebo via the intravenous (IV) route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy.

Reporting group title	GSK2831781 300 mg IV
-----------------------	----------------------

Reporting group description:

Participants were administered GSK2831781 300 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy.

Reporting group title	GSK2831781 150 mg IV
-----------------------	----------------------

Reporting group description:

Participants were administered GSK2831781 150 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy.

Reporting group title	GSK2831781 450 mg IV
-----------------------	----------------------

Reporting group description:

Participants were administered GSK2831781 450 milligrams (mg) via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy.

Reporting group title	GSK2831781 45 mg IV
-----------------------	---------------------

Reporting group description:

Participants were administered GSK2831781 45 mg via the IV route on Day 1, Weeks 2, 6 and 10. At Week 10, participants underwent Induction assessment including endoscopy.

Reporting group title	Placebo SC
-----------------------	------------

Reporting group description:

Participants from the placebo arm identified as responders based on Week 10 assessments during the Induction Phase received placebo subcutaneously (SC) every 4 weeks from Weeks 14 to 26 during the 20 week double-blind extended treatment phase (ETP). At Week 30, participants underwent an assessment following which they were followed up until Week 42.

Reporting group title	GSK2831781 300 mg SC
-----------------------	----------------------

Reporting group description:

Participants from the GSK2831781 arms identified as responders based on Week 10 assessments during the Induction Phase received GSK2831781 300 mg SC every 4 weeks from Weeks 14 to 26 during the 20-week double-blind ETP. At Week 30, participants underwent an assessment following which they were followed up until Week 42.

Reporting group title	Open-label GSK2831781 450 mg IV
-----------------------	---------------------------------

Reporting group description:

Participants identified as non-responders during the double-blind Induction phase at Week 10 were administered GSK2831781 450 mg IV on Weeks 12, 14, 18 and 22 during the open-label (OL) induction phase.

Reporting group title	Open-label GSK2831781 300 mg SC
-----------------------	---------------------------------

Reporting group description:

Participants from the Open-label induction phase who responded at Week 22 entered the 20-week (Week 22 to Week 42) open-label extended treatment phase and received GSK2831781 300 mg SC every 4 weeks from Week 26 until Week 38. Participants were followed up until Week 54.

<b>Serious adverse events</b>	Placebo IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	GSK2831781 450 mg IV	GSK2831781 45 mg IV	Placebo SC
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 48 (12.50%)	0 / 8 (0.00%)	0 / 5 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	3 / 48 (6.25%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	4 / 48 (8.33%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>	GSK2831781 300 mg SC	Open-label GSK2831781 450 mg IV	Open-label GSK2831781 300 mg SC
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 8 (12.50%)	3 / 42 (7.14%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	1 / 8 (12.50%)	2 / 42 (4.76%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Placebo IV	GSK2831781 300 mg IV	GSK2831781 150 mg IV
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 27 (37.04%)	6 / 11 (54.55%)	2 / 10 (20.00%)
<b>Vascular disorders</b>			
Hypertension			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Phlebitis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Pelvic venous thrombosis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Thrombosed varicose vein			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
<b>General disorders and administration site conditions</b>			
Pain			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Asthenia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
<b>Respiratory, thoracic and mediastinal disorders</b>			

Dyspnoea			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pulmonary mass			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Mixed anxiety and depressive disorder			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Somatic symptom disorder			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Depressed mood			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Investigations			
Heart rate decreased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Body temperature increased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			



subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Glucose urine present subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Myocardial fibrosis subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Arrhythmia subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Thrombocytosis			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 27 (3.70%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Ear pain			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Colitis ulcerative			
subjects affected / exposed	1 / 27 (3.70%)	2 / 11 (18.18%)	2 / 10 (20.00%)
occurrences (all)	1	2	2
Dental caries			

subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Malabsorption			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatitis toxic			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			

subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Alopecia			
subjects affected / exposed	1 / 27 (3.70%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 27 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthropathy			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 27 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Arthralgia			

subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Infections and infestations			
COVID-19			
subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Nasopharyngitis			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 11 (9.09%) 1	1 / 10 (10.00%) 1
Upper respiratory tract infection			
subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Herpes zoster			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Rhinitis			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Sinusitis			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Tooth abscess			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Urinary tract infection			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Suspected COVID-19			
subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Gingivitis			
subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Tinea pedis			
subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0

Nasal herpes subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Metabolism and nutrition disorders			
Dehydration subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0

<b>Non-serious adverse events</b>	GSK2831781 450 mg IV	GSK2831781 45 mg IV	Placebo SC
Total subjects affected by non-serious adverse events subjects affected / exposed	26 / 48 (54.17%)	2 / 8 (25.00%)	1 / 5 (20.00%)
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0
Phlebitis subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Haematoma subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Pelvic venous thrombosis subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Thrombosed varicose vein			

subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
General disorders and administration site conditions			
Pain			
subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Asthenia			
subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Fatigue			
subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Peripheral swelling			
subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Pyrexia			
subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0
Oropharyngeal pain			
subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Pulmonary mass			
subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Psychiatric disorders			
Mixed anxiety and depressive disorder			
subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Somatic symptom disorder			
subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0

Depressed mood subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Investigations			
Heart rate decreased subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	1 / 5 (20.00%) 1
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Glucose urine present subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Cardiac disorders			



Tachycardia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Myocardial fibrosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Arrhythmia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 48 (8.33%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	6	0	0
Migraine			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Thrombocytosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Vitreous floaters			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Colitis ulcerative			
subjects affected / exposed	12 / 48 (25.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	13	0	0
Dental caries			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Malabsorption			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	2 / 48 (4.17%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Abdominal distension			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			

subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Frequent bowel movements subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Hepatobiliary disorders Hepatitis toxic subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Pyoderma gangrenosum subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Urticaria			

subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthropathy subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0
Arthritis subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Infections and infestations COVID-19 subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1	1 / 8 (12.50%) 1	0 / 5 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
Rhinitis			

subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	2 / 48 (4.17%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
Suspected COVID-19			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tinea pedis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Nasal herpes			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 48 (0.00%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Decreased appetite			
subjects affected / exposed	1 / 48 (2.08%)	0 / 8 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0

Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 8 (0.00%) 0	0 / 5 (0.00%) 0
--	---------------------	--------------------	--------------------

<b>Non-serious adverse events</b>	GSK2831781 300 mg SC	Open-label GSK2831781 450 mg IV	Open-label GSK2831781 300 mg SC
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 8 (37.50%)	18 / 42 (42.86%)	2 / 7 (28.57%)
<b>Vascular disorders</b>			
Hypertension subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Phlebitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Haematoma subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Pelvic venous thrombosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Thrombosed varicose vein subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
<b>General disorders and administration site conditions</b>			
Pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0

Pyrexia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Pulmonary mass subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Psychiatric disorders Mixed anxiety and depressive disorder subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Somatic symptom disorder subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Depressed mood subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Investigations Heart rate decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0

Weight decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Glucose urine present subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Myocardial fibrosis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Arrhythmia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	2 / 42 (4.76%) 2	0 / 7 (0.00%) 0



Migraine subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	4 / 42 (9.52%) 4	0 / 7 (0.00%) 0
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 42 (2.38%) 1	0 / 7 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Vitreous floaters subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0

Colitis ulcerative			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Dental caries			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Malabsorption			
subjects affected / exposed	1 / 8 (12.50%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Diarrhoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatitis toxic			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 42 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pyoderma gangrenosum			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthropathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Myalgia			

subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	1 / 8 (12.50%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Tooth abscess			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Suspected COVID-19			
subjects affected / exposed	0 / 8 (0.00%)	2 / 42 (4.76%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Gingivitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Tinea pedis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nasal herpes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 8 (0.00%)	1 / 42 (2.38%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Iron deficiency			
subjects affected / exposed	0 / 8 (0.00%)	2 / 42 (4.76%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Decreased appetite			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 42 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 January 2019	Amendment 1: Changes requested by Medicines and Healthcare products Regulatory Agency (MHRA)
10 September 2019	Amendment 2: Exclusion criteria adapted to allow participants following inadequate response, loss of response, or intolerance to up to three classes of approved advanced therapies for ulcerative colitis. Amalgamation of comments from regulatory authorities. Incorporation of stratification for Japanese ethnicity, and Protocol clarifications and corrections
03 September 2020	Amendment 3: Provision for home healthcare (home nursing and telemedicine) approaches for selected study visits where applicable country and local regulations and infrastructure allow. Clarification of COVID-19 specific measures. Correction of protocol inconsistencies and clarification of study procedures and objectives, including the time frame of the collection of safety data in the induction period (primary endpoint). Estimands have been introduced following best practice and the term 'evaluable' has been removed for consistency. The study retains the principle that if more participants (of those required for the hypothetical estimand) drop out than has been planned for, then additional participants may be recruited. The primary analysis will now fit the originally planned dose-response model using a Bayesian framework with non-informative priors. This allows consistency in estimation across endpoints, including when data are missing, but does not change the sample size required.
12 November 2020	Amendment 4: Main changes: Response to Health Authority feedback following review of Protocol Amendment 3, regarding the first SC dose administration and post dose monitoring. Minor changes: clarification for investigators and administrative corrections

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported